for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Janssen Submits NDA In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's Enhanze Tech For Patients With Multiple Myeloma

April 26 (Reuters) - Halozyme Therapeutics Inc:

* JANSSEN SUBMITS NDA IN JAPAN FOR DARATUMUMAB SUBCUTANEOUS FORMULATION UTILIZING HALOZYME’S ENHANZE TECH FOR PATIENTS WITH MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up